Related Experiment Video
Updated: Aug 2, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
A lesson for the maestro of the replication fork: Targeting the protein-binding interface of proliferating cell
Vijay Kumar Bhardwaj1,2,3, Rituraj Purohit1,2,3
1Structural Bioinformatics Lab, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur, Himachal Pradesh, India.
Abstract:
The proliferating cell nuclear antigen (PCNA) has emerged as a promising candidate for the development of novel cancer therapeutics. PCNA is a nononcogenic mediator of DNA replication that regulates a diverse range of cellular functions and pathways through a comprehensive list of protein-protein interactions. The hydrophobic binding pocket on PCNA offers an opportunity for the development of inhibitors to target various types of cancers and modulate protein-protein interactions. In the present study, we explored the binding modes and affinity of molecule I1 (standard molecule) with the previously suggested dimer interface pocket and the hydrophobic pocket present on the frontal side of the PCNA monomer. We also identified potential lead molecules from the library of in-house synthesized 3-methylenisoindolin-1-one based molecules to inhibit the protein-protein interactions of PCNA. Our results were based on robust computational methods, including molecular docking, conventional, steered, and umbrella sampling molecular dynamics simulations. Our results suggested that the standard inhibitor I1 interacts with the hydrophobic pocket of PCNA with a higher affinity than the previously suggested binding site. Also, the proposed molecules showed better or comparable binding free energies as calculated by the Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) approach and further validated by enhanced umbrella sampling simulations. In vitro and in vivo methods could test the computationally suggested molecules for advancement in the drug discovery pipeline.
Insights
Researchers explored novel cancer therapeutics targeting proliferating cell nuclear antigen (PCNA). Computational methods identified promising 3-methylenisoindolin-1-one molecules that bind effectively to PCNA, offering potential for new drug development.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Proliferating cell nuclear antigen (PCNA) is crucial for DNA replication and cellular functions.
- PCNA's protein-protein interactions and hydrophobic binding pocket present therapeutic targets for cancer.
- Developing inhibitors for PCNA could lead to novel cancer treatments.
Purpose of the Study:
- To investigate the binding modes and affinity of a standard inhibitor (I1) with PCNA.
- To identify potential lead molecules from a library of 3-methylenisoindolin-1-one derivatives.
- To evaluate the efficacy of these molecules in inhibiting PCNA protein-protein interactions.
Main Methods:
- Molecular docking simulations.
- Conventional, steered, and umbrella sampling molecular dynamics simulations.
- Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) calculations.
Main Results:
- The standard inhibitor I1 demonstrated higher affinity for PCNA's hydrophobic pocket compared to other sites.
- Novel 3-methylenisoindolin-1-one molecules exhibited favorable binding free energies.
- Computational findings were validated using enhanced umbrella sampling simulations.
Conclusions:
- The hydrophobic pocket of PCNA is a key target for inhibitor development.
- Synthesized 3-methylenisoindolin-1-one derivatives show promise as PCNA inhibitors.
- Further in vitro and in vivo studies are warranted to advance these compounds in the drug discovery pipeline.
Related Concept Videos
Negative Regulator Molecules
The DNA Replication Fork
DNA Damage can Stall the Cell Cycle
Restarting Stalled Replication Forks
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
DNA Damage Can Stall the Cell Cycle

